Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 93
  • 356
  • 157
  • 13
  • 16
  • 327
  • 353
  • 3

Found 356 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

12 years - 99 years
All genders
Phase 2
Interventional
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
 Detection of cell-free circulating tumor DNA in patients with glioblastma undergoing treatment with first-line chemoradiotherapy
99 years or below
All genders
Glioblastoma (GBM) is the most common primary brain tumor in adults and is uniformly fatal. During standard adjuvant treatment for GBM following initial surgical resection of the tumor, patients are treated with a combination of radiation and chemotherapy. During and after this adjuvant treatment, patients are monitored for disease progression …
18 years or above
All genders
Phase 1/2
Interventional
The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat …
 Durvalumab (MEDI4736) with Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma
18 years - 99 years
All genders
Phase 3
Interventional
Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and pemetrexed. T Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the …
18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
99 years or below
All genders
Lymphoma survivors who were treated with prior radiation therapy have been shown to have an increased risk of cancers of the gastrointestinal system. This increased cancer risk may be due to damage to cells in your gastrointestinal system that is caused at the time of radiation. This research is being …
99 years or below
All genders
Phase 1
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
18 years - 99 years
All genders
Phase 2
Interventional
This study involves metastatic, stage 4 cancer, that has spread to your abdominal cavity and your cancer surgeon recommends surgery to remove cancer tumors from your abdomen. The purpose of this research study is to learn if the investigational study drug, pegsitacianine, helps in seeing the metastatic cancer disease left …
 Physiologic MR Imaging in Distinguishing Benign from Malignant Salivary Gland Tumors
18 years - 99 years
All genders
The purpose of this research study is to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and also aid in the prediction of disease progression. It is important to determine whether the salivary gland tumor is cancerous prior to operation because this information …
211 - 220 of 356